ITGAX and asthma: In accordance with the findings of this study, a previous study using OVA-induced asthma models reported that CD11c+CD11blow AMs were significantly reduced upon OVA challenge but were restored upon treatment with human MSCs, and in vivo depletion of AMs abrogated the therapeutic effects of human MSCs on allergic airway inflammation and AHR21.